Display options
Cite
Minassian AM, McShane H. Tuberculosis vaccines: present and future. Expert Rev Respir Med. 2008;2(6):721-38doi: 10.1586/17476348.2.6.721.
Minassian, A. M., & McShane, H. (2008). Tuberculosis vaccines: present and future. Expert review of respiratory medicine, 2(6), 721-38. https://doi.org/10.1586/17476348.2.6.721
Minassian, Angela M, and McShane, Helen. "Tuberculosis vaccines: present and future." Expert review of respiratory medicine vol. 2,6 (2008): 721-38. doi: https://doi.org/10.1586/17476348.2.6.721
Minassian AM, McShane H. Tuberculosis vaccines: present and future. Expert Rev Respir Med. 2008 Dec;2(6):721-38. doi: 10.1586/17476348.2.6.721. PMID: 20477235.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Respir Med. 2008 Dec;2(6):721-38. doi: 10.1586/17476348.2.6.721.

Tuberculosis vaccines: present and future.

Expert review of respiratory medicine

Angela M Minassian, Helen McShane

Affiliations

  1. The Jenner Institute, University of Oxford, Old Road Campus Research Building, Level 2, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK. [email protected]

PMID: 20477235 DOI: 10.1586/17476348.2.6.721

Abstract

There has never been a greater need for a new protective tuberculosis vaccine. Bacille Calmette-Guerin remains the cornerstone of any vaccine strategy, but improving its immunogenicity and efficacy has now become an urgent global health priority. This review discusses the main vaccines currently in clinical development and other novel vaccine strategies in the pipeline. It addresses the key questions in vaccine design, including antigen selection, route of vaccine delivery and immune correlates of vaccine-induced protection. There is an opportunity to identify such correlates from ongoing and future Phase II/III trials and, as these emerge, they can be used to validate the most relevant and predictive animal models with which to develop the next generation of new vaccines.

Publication Types

Grant support